About biomérieux sa - BMXMF
bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. It develops testing, detection, and other laboratory system for the analysis of cancer, diseases, and infections caused by bacteria, virus, and fungi. The company was founded Alain Mérieux in 1963 and is headquartered in Marcy l'Etoile, France.
BMXMF At a Glance
bioMérieux SA
376, chemin de l'Orme
Marcy l'Etoile, Auvergne-Rhone-Alpes 69280
| Phone | 33-4-78-87-20-00 | Revenue | 4.59B | |
| Industry | Medical Specialties | Net Income | 448.61M | |
| Sector | Health Technology | 2025 Sales Growth | 6.691% | |
| Fiscal Year-end | 12 / 2026 | Employees | 15,078 | |
| View SEC Filings |
BMXMF Valuation
| P/E Current | 28.011 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 34.07 |
| Price to Sales Ratio | 3.352 |
| Price to Book Ratio | 3.173 |
| Price to Cash Flow Ratio | 17.30 |
| Enterprise Value to EBITDA | 13.909 |
| Enterprise Value to Sales | 3.325 |
| Total Debt to Enterprise Value | 0.035 |
BMXMF Efficiency
| Revenue/Employee | 304,621.737 |
| Income Per Employee | 29,752.602 |
| Receivables Turnover | 4.124 |
| Total Asset Turnover | 0.734 |
BMXMF Liquidity
| Current Ratio | 2.386 |
| Quick Ratio | 1.47 |
| Cash Ratio | 0.535 |
BMXMF Profitability
| Gross Margin | 55.858 |
| Operating Margin | 16.087 |
| Pretax Margin | 12.342 |
| Net Margin | 9.767 |
| Return on Assets | 7.165 |
| Return on Equity | 9.782 |
| Return on Total Capital | 8.37 |
| Return on Invested Capital | 9.044 |
BMXMF Capital Structure
| Total Debt to Total Equity | 11.248 |
| Total Debt to Total Capital | 10.111 |
| Total Debt to Total Assets | 8.277 |
| Long-Term Debt to Equity | 8.045 |
| Long-Term Debt to Total Capital | 7.231 |